RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY

被引：17

作者：

Finch, Rebecca ^{[1
]}

Sostelly, Alexandre ^{[2
]}

Sue-Ling, Kim ^{[3
]}

Blaeuer, Angela ^{[2
]}

Duchateau-Nguyen, Guillemette ^{[2
]}

Ukarma, Lidia ^{[2
]}

Petry, Claire ^{[2
]}

Ravva, Patanjali ^{[2
]}

Villiger, Peter ^{[4
]}

Junker, Uwe ^{[2
]}

机构：

[1] Roche Prod Ltd, Welwyn Garden City, England

[2] Roche Innovat Ctr Basel, Basel, Switzerland

[3] Roche Innovat Ctr New York, New York, NY USA

[4] Inselspital Bern, Bern, Switzerland

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷

关键词：

D O I：

10.1136/annrheumdis-2019-eular.3028

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0224

引用

页码：189 / 189

页数：1

共 50 条

[31] OUTCOMES WITH TOCILIZUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TUMOR NECROSIS FACTOR-α THERAPY.
Emery, Paul
Keystone, Edward
Tony, Hans-Peter
Cantagrel, Alain
van Vollenhoven, Ronald F.
Sanchez-Ortiz, Adriana
Vernon, Emma
Roseti, Stephanie
Kremer, Joel
JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1087 - 1087
[32] FIRST-IN-PATIENT STUDY OF NAMILUMAB, AN ANTI-GM-CSF MONOCLONAL ANTIBODY, IN ACTIVE RHEUMATOID ARTHRITIS: RESULTS OF THE PRIORA PHASE IB STUDY
Huizinga, T. W. J.
Batalov, A.
Yablanski, K.
Stoilov, R.
Lloyd, E.
Wagner, T.
Saurigny, D.
Souberbielle, B.
Esfandiari, E.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 733 - 733
[33] PHARMACOKINETICS AND PHARMACODYNAMICS OF MLTA3698A, A NOVEL ANTI-LYMPHOTOXIN-α MONOCLONAL ANTIBODY, IN A PHASE I STUDY WITH RHEUMATOID ARTHRITIS PATIENTS
Zheng, Y.
Xiao, J.
Williams, M.
Woods, C.
Fuh, F.
Emu, B.
Tang, M.
Visich, J. F.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S28 - S29
[34] Baricitinib versus placebo or adalimumab in patients with active rheumatoid arthritis and an inadequate response to background methotrexate therapy: Results of a phase 3 study
Taylor, P. C.
Keystone, E. C.
van der Heijde, D.
Tanaka, Y.
Ishii, T.
Emoto, K.
Yang, L.
Arora, V
Gaich, C.
Rooney, T.
Schlichting, D.
Macias, W. L.
de Bono, S.
Weinblatt, M. E.
SWISS MEDICAL WEEKLY, 2016, 146 : 9S - 9S
[35] Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
Antoni, C
Kalden, JR
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (06) : S73 - S77
[36] Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis A Randomized Phase IIa Trial
Senolt, Ladislav
Leszczynski, Piotr
Dokoupilova, Eva
Goethberg, Marie
Valencia, Xavier
Hansen, Brian Bekker
Canete, Juan D.
ARTHRITIS & RHEUMATOLOGY, 2015, 67 (06) : 1438 - 1448
[37] EFFICACY OF LEVILIMAB, NOVEL MONOCLONAL ANTI-IL-6 RECEPTOR ANTIBODY, IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: 1-YEAR RESULTS OF PHASE 2 AURORA STUDY
Mazurov, V.
Zotkin, E.
Ilivanova, E.
Kropotina, T.
Plaksina, T.
Nesmeyanova, O.
Soroka, N.
Kundzer, A.
Lutskii, A.
Dokukina, E.
Eremeeva, A.
Zinkina-Orihan, A.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 633 - 634
[38] Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study
Genovese, Mark C.
Fleischmann, Roy
Kivitz, Alan J.
Rell-Bakalarska, Maria
Martincova, Renata
Fiore, Stefano
Rohane, Patricia
van Hoogstraten, Hubert
Garg, Anju
Fan, Chunpeng
van Adelsberg, Janet
Weinstein, Steven P.
Graham, Neil M. H.
Stahl, Neil
Yancopoulos, George D.
Huizinga, Tom W. J.
van der Heijde, Desiree
ARTHRITIS & RHEUMATOLOGY, 2015, 67 (06) : 1424 - 1437
[39] A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Genovese, Mark C.
Greenwald, Maria
Cho, Chul-Soo
Berman, Alberto
Jin, Ling
Cameron, Gregory S.
Benichou, Olivier
Xie, Li
Braun, Daniel
Berclaz, Pierre-Yves
Banerjee, Subhashis
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (07) : 1693 - 1704
[40] Mavrilimumab (an Anti-GM-CSFRα Monoclonal Antibody) in Subjects with Rheumatoid Arthritis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
Burmester, Gerd R.
Weinblatt, Michael E.
Barbarash, Olga
Vatutin, Mykola
Szombati, Istvan
Stoilov, Rumen
Matsievskaya, Galina
Venalis, Algirdas
Esfandiari, Ehsanollah
Grove, Geraldine
Saurigny, Didier
Sleeman, Matthew A.
Godwood, Alex
Magrini, Fabio
ARTHRITIS AND RHEUMATISM, 2011, 63 (12): : 4044 - 4044

← 1 2 3 4 5 →